Variant Bio is leveraging the power of human genetics to develop innovative therapies aimed at addressing significant unmet medical needs. The company focuses on studying populations with exceptional health-related traits, which can provide critical insights into the molecular basis of diseases. By utilizing genetic data, Variant Bio aims to enhance the success rates of clinical trials and streamline drug development processes. Their research spans various therapeutic areas, including inflammation-immunology, fibrosis, and kidney diseases, with a commitment to precision medicine that tailors treatments to individual genetic profiles.

The company emphasizes ethical collaboration with underrepresented populations, forming partnerships with communities, academic institutions, and healthcare professionals to conduct genetic studies. Variant Bio's approach includes co-designing research projects with local researchers and communities, ensuring that the benefits of their findings are shared equitably. Their pipeline consists of multiple programs at various stages, focusing on both common and orphan diseases, and they prioritize targets with strong human genetic validation to drive their drug discovery efforts. Through these initiatives, Variant Bio aims to transform the landscape of drug development while respecting the cultural and ethical considerations of the populations they work with.

United States

Variant Bio is developing therapies that will improve global health by studying the genes of people who are outliers for medically relevant traits. They’re using cutting-edge sequencing technology, statistical genetics, and machine learning to identify entirely new therapeutic targets.

Variant Bio

Company Details